Evidence map›Paper›PMID 35891654›Full record

ArticleJournal of advanced veterinary and animal research2022

Point-specific interactions of isovitexin with the neighboring amino acid residues of the hACE2 receptor as a targeted therapeutic agent in suppressing the SARS-CoV-2 influx mechanism.

Nourin Ferdausi, Samarth Islam, Fahmida Hoque Rimti, Syeda Tasnim Quayum, Efat Muhammad Arshad, Aashian Ibnat, Tamnia Islam, Adittya Arefin, Tanzila Ismail Ema, Partha Biswas and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced veterinary and animal research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Anti-adherent effects ofVeterinary world · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Identification of antidiabetic inhibitors fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  17. Article
  18. Review
  19. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  20. Study ofMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nourin FerdausiBiochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Samarth IslamDepartment of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh.
Fahmida Hoque RimtiBachelor of Medicine and Surgery, Chittagong Medical College, Chittagong, Bangladesh.
Syeda Tasnim QuayumDepartment of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh.
Efat Muhammad ArshadDepartment of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh.
Aashian IbnatDepartment of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh.
Tamnia IslamWolfson Institute for Biomedical Research, Division of Medicine, University College London, London, United Kingdom.
Adittya ArefinWolfson Institute for Biomedical Research, Division of Medicine, University College London, London, United Kingdom.
Tanzila Ismail EmaDepartment of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh.
Partha BiswasDepartment of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, Bangladesh.
Dipta DeyDepartment of Biochemistry and Molecular Biology, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.
Salauddin Al AzadFermentation Engineering Major, School of Biotechnology, Jiangnan University, Wuxi, PR China.
North South University · BDBangabandhu Sheikh Mujibur Rahman Science and Technology University · BDUniversity College London · GBWolfson Foundation · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Despite the development of several vaccines against severe acute respiratory syndrome coronavirus-2, the need for an additional prophylactic agent is evident. In recent Materials and Methods: The pharmacokinetic profile of isovitexin was analyzed. The crystal structure of the hACE2 receptor and the ligand isovitexin were docked to form a ligand-protein complex following molecular optimization. To determine the isovitexin-hACE2 complex stability, their binding affinity, hydrogen bonding, and hydrophobic interactions were studied. Lastly, the root mean square deviation (RMSD), root mean square fluctuation, solvent accessible surface area, molecular surface area, radius of gyration (Rg), polar surface area, and principal component analysis values were found by simulating the complex with molecular dynamic (MD). Results: The predicted Lethal dose Conclusions: Isovitexin is a phytochemical with a reasonable bioactivity and safety profile for use in humans, and it can potentially be used as a hACE2-specific therapeutic to inhibit COVID-19 infection.

Indexed as

COVID-19dynamic simulationhACE2 receptorisovitexinmolecular dockingPhytochemicalprophylactic agenttarget specificity

Identifiers

PMID35891654
PMCPMC9298103
OpenAlexW4285253652

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.